RGS5
RGS5proteinG-protein regulator maintaining endothelial barrier function; miR-330-3p-suppressed in MI progression.
Pathway placement
Cascade stepEndothelial activation & erosion
Confidencehigh
RationaleRegulator of G-protein signaling; loss impairs endothelial barrier integrity and promotes dysfunction.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000143248
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I20
C — confounder / Type-II49
A — assay feasibility68
E — evidence strength18
T1DI (composite)4
Specificity differential (R−C)-28.6
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- miR-330-3p promotes acute coronary syndrome progression via targeting RGS5.Journal of cardiothoracic surgery · 2026 · PMID 42015195 · doi
- Down-regulated RGS5 by genetic variants impairs endothelial cell function and contributes to coronary artery disease.Cardiovascular research · 2021 · PMID 31605122 · doi